
Oct 16, 2026 · 46 min
Listen from 4:14
Listen at 4:14
FDA turnover and ESMO put biotech catalysts under scrutiny
Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is Watching
The episode connects regulatory uncertainty with a dense pipeline of oncology, ophthalmology, and clinical-development catalysts that could move biotech stocks.
- 1FDA leadership turnover, workforce reductions, and more PDUFA extensions are reshaping the regulatory backdrop for biotech investors.
- 2ESMO’s upcoming data may offer an early read on oncology themes that later surface at ASCO.
- 3The watchlist spans Aldeyra, NRx, Unicycive, Vivani, and Fractyl as clinical and regulatory milestones approach.
Don't miss
Sheff’s discussion of Aldeyra’s positive Phase 3 data shows how a single ophthalmology result can become a broader clinical and regulatory trading catalyst.
The brief
John Gagliano and Sheff Sheffield frame the discussion around a biotech market facing both regulatory uncertainty and a crowded calendar of clinical catalysts.
Sheff points to FDA workforce reductions, senior leadership turnover, novel-drug approvals, and more PDUFA extensions as signs of a changing regulatory environment.
The hosts treat ESMO as an important oncology checkpoint, with presentations from large pharmaceutical companies and smaller partners potentially previewing themes for ASCO.
The catalyst watchlist moves from Aldeyra’s positive Phase 3 ophthalmology data to upcoming developments at NRx, Unicycive, Vivani, and Fractyl.
The episode’s central tension is whether company-specific milestones can outweigh the uncertainty created by evolving FDA leadership and review dynamics.
What was said on this episode
33 statements · 26 positive · 1 negative · 2 mixed · 4 neutral
FDA’s CEDAR approved 46 novel drugs despite an 18% workforce reduction.
“Cedar approved 46 novel drugs despite an 18% reduction in force across the FDA.”
Listen at 4:14
FDA leadership changes could occur in 2027.
“I think 2027 could be the year that we see this change with the FDA.”
Listen at 6:44
- Chef Stationon FDA leadership changesNeutral6:44
FDA leadership changes could occur in 2027
“2027 could be the year that we see this change with the FDA”
Listen at 6:44
- Chef Stationon ESMO merger activityPositive7:33
ESMO season typically brings merger activity involving smaller companies.
“I just think this is usually where we start to see some activity with mergers with smaller companies.”
Listen at 7:33
ESMO will provide substantial new oncology data.
“I think ESMO is going to provide a lot of new data”
Listen at 8:43
Small companies’ ESMO presentations may determine their prospects into 2027.
“there's a lot of smaller companies that have presentations that are going to pretty much make or break what they do moving forward into 2027.”
Listen at 8:51
- Chef Stationon Aldeyra Therapeutics FDA dispute resolutionPositive14:14
Aldeyra should submit its FDA dispute resolution soon
“we should hear. you know, in the next week or so that they've actually submitted this”
Listen at 14:14
Aldeyra’s potential AbbVie partnership would have approximately 60–40 economics.
“it would also allow them to go into a partnership where it's pretty much 60-40 AbbVie.”
Listen at 15:09
- Chef Stationon Aldeyra TherapeuticsPositive16:25
Aldeyra could receive FDA approval in early January.
“we're probably looking at early January for them to get approved”
Listen at 16:25
- Chef Stationon Aldeyra TherapeuticsPositive16:48
Chef views Aldeyra’s current position favorably
“I really like where the company is at right now”
Listen at 16:48
- Chef Stationon InovioPositive19:08
Inovio appears well positioned ahead of its FDA decision
“they look like they're in good standing”
Listen at 19:08
- Chef Stationon InovioPositive20:29
Inovio’s stock could rise around its October 30 FDA decision.
“with that FDA decision on October 30th, I think as we see the market starts to turn, we might start to see that one really pop up.”
Listen at 20:29
- Chef Stationon InovioPositive20:37
Inovio could rise around its October FDA decision
“we might start to see that one really pop up”
Listen at 20:37
Chef sees Unicycive’s potential inspection outcome as an opportunity
“I think it'll be a great opportunity”
Listen at 25:50
- Chef Stationon Unicycive phosphatemia therapyPositive25:53
Unicycive’s three-pill regimen could dominate the phosphatemia market.
“UNCY taking the three pills a day are going to have a lock on the phosphatemia market.”
Listen at 25:53
- Chef Stationon Vivani NPM 139Positive28:35
Additional weight loss with NPM 139 plus semaglutide would materially benefit Vivani.
“if weight loss is shown in addition to using Wagovi or semaglutide, it's going to be big for the company.”
Listen at 28:35
- Chef Stationon ProQR AX0810–Eli Lilly collaborationPositive29:40
ProQR’s AX0810 collaboration with Eli Lilly includes potential milestone payments upon Phase 1 success.
“they've got a partnership with Eli Lilly, a collaboration that includes potential data and update and milestone payments if they're successful in there. phase one study with this AX0810.”
Listen at 29:40
- Chef Stationon Fractyl HealthPositive31:34
Fractyl Health plans to file a de novo application in December after receiving data.
“they're going to be filing a de novo in the fourth quarter, um, in, in December, you know, once they get this data”
Listen at 31:34
- Chef Stationon Fractyl Health REVEAL-1 pivotal cohortNeutral32:24
Fractyl Health’s pivotal cohort data should arrive soon
“data should be in the next week or two”
Listen at 32:24
- Chef Stationon OsteoVax OST-HER2Positive33:24
OsteoVax could receive accelerated approval in December
“if they get accelerated approval in December”
Listen at 33:24
- Chef Stationon OS Therapies priority review voucherPositive33:34
OS Therapies could sell the priority review voucher for $200–250 million.
“which they can sell for 200 to 250 million”
Listen at 33:34
- Chef Stationon Pasithea TherapeuticsNegative35:08
Pasithea Therapeutics’ stock has recently declined
“that stock has been getting hit”
Listen at 35:08
- Chef Stationon Pasithea TherapeuticsPositive35:43
Pasithea does not currently need to conduct a reverse split.
“they don't have the need to have to do a reverse split.”
Listen at 35:43
- Chef Stationon Kineta CD46-directed ADCMixed38:02
Kineta’s fourth-quarter data could materially affect the company
“they've got data in the fourth quarter that could be significant for the company”
Listen at 38:02
- Chef Stationon Ovid OV329Positive38:42
OV329’s meaningful seizure reduction would be the key fourth-quarter driver for Ovid.
“how that translate into a meaningful seizure reduction is going to be really the key driver in the fourth quarter.”
Listen at 38:42
- Chef Stationon Ovid Therapeutics OV329Neutral38:52
Ovid’s OV329 data will be reported at year end
“that data is going to be year end readout”
Listen at 38:52
- Chef Stationon Samus Therapeutics mavorixafortidePositive40:15
Samus’s mavorixafortide demonstrated sustained improvements in lung function and respiratory quality of life.
“their drug, Mugramastin, demonstrated continuous long-term improvement in lung function and respiratory health-related quality of life.”
Listen at 40:15
- Chef Stationon Gossamer Bio seralutinib NDANeutral41:26
Gossamer’s NDA acceptance was expected around November 27.
“So it should be around November 27th because it's usually 60 days from when they send it out.”
Listen at 41:26
- Chef Stationon Gossamer Bio NDA acceptancePositive41:26
Gossamer’s NDA acceptance could occur around November 27
“it should be around November 27th because it's usually 60 days from when they send it out”
Listen at 41:26
- Chef Stationon Gossamer Bio seralutinibPositive41:45
Gossamer’s seralutinib data appears favorable.
“their data looks good.”
Listen at 41:45
- Chef Stationon Gossamer BioPositive42:27
Gossamer Bio is extremely well funded.
“I think it's extremely well-funded.”
Listen at 42:27
- Chef Stationon Gossamer Bio NDA reviewPositive42:55
Gossamer’s financing suggests investors expect no refuse-to-file decision
“I think obviously with this, you know. The structured financing investors and institutions are pretty confident that that's not going to happen”
Listen at 42:55
- Chef Stationon Gossamer Bio FDA reviewPositive43:34
Gossamer’s two FDA objections were likely reclassified for substantive review rather than refusal to file.
“it does mean that the two objections are most likely to have produced a refuse to file. have been reclassified as matters for substantive review”
Listen at 43:34
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Books & mentions
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.